Evan David Seigerman

Stock Analyst at BMO Capital

(1.93)
# 3,087
Out of 4,910 analysts
45
Total ratings
39.02%
Success rate
-7.12%
Average return

Stocks Rated by Evan David Seigerman

Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27$2
Current: $3.17
Upside: -36.91%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22$26
Current: $22.67
Upside: +14.69%
Regeneron Pharmaceuticals
Jun 2, 2025
Maintains: Outperform
Price Target: $800$600
Current: $570.60
Upside: +5.15%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96$110
Current: $66.25
Upside: +66.04%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24$28
Current: $23.44
Upside: +19.45%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20$10
Current: $7.94
Upside: +26.02%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105$64
Current: $70.58
Upside: -9.32%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105$96
Current: $84.11
Upside: +14.14%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208$215
Current: $191.45
Upside: +12.30%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362$346
Current: $308.97
Upside: +11.99%
Maintains: Outperform
Price Target: $83$100
Current: $18.21
Upside: +449.06%
Reiterates: Outperform
Price Target: $33$36
Current: $25.32
Upside: +42.18%
Maintains: Outperform
Price Target: $9$3
Current: $7.08
Upside: -57.63%
Maintains: Outperform
Price Target: $369$396
Current: $806.80
Upside: -50.92%